Zifi 50 DT Tablet contains Cefixime 50 mg, a third-generation cephalosporin antibiotic effective against a broad spectrum of gram-positive and gram-negative bacteria. It is primarily indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, otitis media, pharyngitis, and gonorrhea. Cefixime exerts its bactericidal action by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. The dispersible tablet formulation allows for convenient administration, especially in pediatric and geriatric patients who may have difficulty swallowing conventional tablets. Zifi 50 DT is rapidly absorbed from the gastrointestinal tract, achieving peak plasma concentrations within 2 to 6 hours, and is primarily excreted unchanged via the kidneys. Dosage should be individualized based on the severity of infection, patient age, and renal function. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, abdominal pain, and hypersensitivity reactions including rash and pruritus. It is contraindicated in patients with known hypersensitivity to cephalosporins or penicillins. Caution is advised in patients with renal impairment and a thorough assessment of potential drug interactions should be conducted prior to initiation. Zifi 50 DT should be used under medical supervision to ensure appropriate antimicrobial stewardship and to minimize the risk of resistance development.